Intellia doses first patient as hereditary angioedema gene editing therapy lands in clinic

After making headlines this summer with first-in-human gene editing results, Intellia’s next therapy has officially landed in the clinic in patients with hereditary angioedema (HAE).

The company said it Monday is had dosed the first patient in the phase 1/2 clinical trial of NTLA-2002.